reports
- Jacob Mekhael
mdxhealth FIRST LOOK: 3Q24 results come with upgraded FY24 guidance
mdxhealth reported 3Q24 revenue growth of 21% y/y, while management upgraded FY24 guidance to $ 87-89m (previously $ 85-87m) reflecting increased confidence in utilisation from healthcare providers. The goal to reach positive adjusted EBITDA by 1H25 remains on track, and now starts to come into view, while management guided for 20% topline growth for FY25. We reiterate our $ 4.2 TP and Buy rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
MDxHealth Reports Results for the Third Quarter and Nine-Month Period ...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGar...
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
MDxHealth to Present Third Quarter 2024 Financial Results and Corporat...
MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6 MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 () – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third ...
- Guy Sips
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
Biotalys FIRST LOOK: Fresh cash through € 15m private placement
Biotalys raises € 15m through a private placement with a strong syndicate of existing investors AvH and AIF, as well as new investor ASR. The new shares are issued at € 2.83, representing a discount of 10% on the 30-day VWAP. Proceeds will be used to support Evoca's regulatory filing, advance the pipeline and strengthen the Agrobody platform. We expect the additional funds to extend the cash runway by approx. 4 quarters into mid-2026 (KBCSe), and in the meantime continue to look out for EPA appr...
- Kristof Samoy
NX Filtration HF UF contract win in Saudi Arabia
This morning NXFIL announced a contract win for 800 modules of HF UF modules to Kindasa Water Services (KWS), a private potable water supplier in Saudi Arabia. The order relates to UF membranes and not the high(er) margin dNF membrane modules. We estimate linked revenue recognition in 2024 to be around €1.2m.
- Thomas Vranken
Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline
Biotalys announced the addition of a new biofungicide program to the pipeline. Biofun-8 leverages Biotalys' Agrobody platform and will target Alternaria, an important leaf spot fungus in fruits, vegetables and potato crops. Biotalys estimates a market opportunity around $ 1.1bn. We reiterate our € 6 TP and Buy rating.
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
mdxhealth $ 40m offering to strengthen the cash position
mdxhealth has proposed and priced an offering of 20m shares for $ 40m gross proceeds at $ 2.00 p.s. (21% discount vs. yesterday's close price). The new capital significantly strengthens the company's cash position (1H24: $ 21.3m) and provides runway well beyond the expected adjusted EBITDA profitability point in 1H25. We do note the significant dilution of 20m new shares vs. 27m shares currently outstanding. We adjust our TP from $ 5.7 to $ 4.2, and reiterate a Buy rating.
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 () – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducti...
MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth Announces Launch of Offering of Ordinary Shares MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 () – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the Ordinary Shares being offered...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
mdxhealth Strong growth outlook (Model Update)
Following mdxhealth's 1H24 results, we updated our model to incorporate the new segment reporting. Overall, our topline estimates remain largely unchanged, as we remain optimistic on the company's long-term growth perspectives. We have slightly adjusted our FY24 gross margin estimates downward, but maintain confidence in adjusted EBITDA profitability by 1H25. Our new TP lands at $ 5.70 (previously $ 6.00), while we reiterate a Buy rating.
- Kristof Samoy
NX Filtration 1H24 results & analyst call key take-aways
Mid July NXFIL already informed the markets on its 1H24 revenues when it communicated the appointment of a new CEO. 1H24 revenues landed at €5.9m growing 56% with gross margins maintained at a high 59%. FTE's were flat vs. year end 2023. EBITDA stood at €-6.4m (vs. €-5.3m in 1H23). Guidance remained unchanged calling for revenues >€16m.
- Martijn Den Drijver
ODDO BHF Small & MIDCAP MORNING NEWS - 08/28/2024
We initiate the coverage of Ypsomed with a target price of CHF 495 and an Outperform rating. As a leading developer and manufacturer of a broad portfolio of injection systems for the self-medication of liquid drugs, Ypsomed will benefit from major trends in the healthcare industry. The company is currently in a transformation process to exit non-core activities and to focus on the fast-growing and highly profitable Delivery Systems business. This is expected to lead on our estimates t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.